ID   MCF-7/AnaR-4
AC   CVCL_5A12
SY   MCF7/AnaR-4; AnaR-4
DR   ECACC; 16022519
DR   Wikidata; Q54904356
DR   Ximbio; 152554
RX   PubMed=25625755;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:2704; Anastrozole.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line).
CC   Derived from metastatic site: Pleural effusion.
ST   Source(s): ECACC
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 11
ST   D16S539: 11,12
ST   D18S51: 14
ST   D21S11: 30
ST   D3S1358: 16
ST   D5S818: 11,12
ST   D7S820: 9
ST   D8S1179: 10,14
ST   FGA: 23,25
ST   Penta D: 12
ST   Penta E: 7,12
ST   TH01: 6
ST   TPOX: 9,12
ST   vWA: 14,15
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_1D47 ! MCF-7/S0.5
SX   Female
AG   69Y
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 20-05-21; Version: 11
//
RX   PubMed=25625755; DOI=10.3892/ijo.2015.2850;
RA   Hole S., Pedersen A.M., Hansen S.K., Lundqvist J., Yde C.W.,
RA   Lykkesfeldt A.E.;
RT   "New cell culture model for aromatase inhibitor-resistant breast
RT   cancer shows sensitivity to fulvestrant treatment and cross-resistance
RT   between letrozole and exemestane.";
RL   Int. J. Oncol. 46:1481-1490(2015).
//